Costello Syndrome Latest Advances

Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.

Journal: Journal of comparative effectiveness research

Published: June 19, 2026

Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.

Journal: Current opinion in lipidology

Published: June 17, 2026

A Case of Familial Chylomicronemia Syndrome Caused by a Novel Homozygous GPIHBP1 Mutation Successfully Treated with the Selective PPARα Modulator Pemafibrate.

Journal: Journal of atherosclerosis and thrombosis

Published: June 17, 2026

Molecular characterization of individuals with RASopathies: Spectrum of genetic variants in a large Indian cohort.

Journal: Journal of genetics

Published: June 11, 2026

ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome.

Journal: The Annals of pharmacotherapy

Published: June 06, 2026

Genetic dyslipidemias.

Journal: Annales d'endocrinologie

Published: March 22, 2026

Fresh frozen plasma as functional replacement therapy in early infantile ApoC-II deficiency: a molecularly confirmed case series.

Journal: Journal of pediatric endocrinology & metabolism : JPEM

Published: February 24, 2026

Comparative efficacy and safety of olezarsen vs plozasiran for familial chylomicronemia syndrome: A matching-adjusted indirect comparison.

Journal: Journal of clinical lipidology

Published: February 17, 2026

Resolution of Refractory Multifocal Atrial Tachycardia in Costello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic.

Journal: American journal of medical genetics. Part A

Published: February 09, 2026

Clinical and molecular characterization of 2 novel LPL variants in familial chylomicronemia syndrome.

Journal: Journal of clinical lipidology

Published: January 06, 2026

Clinical and Molecular Portraits of Pediatric RASopathies: A Study of 118 Genotype-Confirmed Cases.

Journal: Clinical genetics

Published: December 27, 2025

2025: The year in cardiovascular disease - the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?

Journal: Archives of medical science : AMS

Published: December 12, 2025

Costello Syndrome Latest Advances

Find the Latest Research About Costello Syndrome

Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.

Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.

Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.

Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.

A Case of Familial Chylomicronemia Syndrome Caused by a Novel Homozygous GPIHBP1 Mutation Successfully Treated with the Selective PPARα Modulator Pemafibrate.

A Case of Familial Chylomicronemia Syndrome Caused by a Novel Homozygous GPIHBP1 Mutation Successfully Treated with the Selective PPARα Modulator Pemafibrate.

Molecular characterization of individuals with RASopathies: Spectrum of genetic variants in a large Indian cohort.

Molecular characterization of individuals with RASopathies: Spectrum of genetic variants in a large Indian cohort.

ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome.

ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome.

Genetic dyslipidemias.

Genetic dyslipidemias.

Fresh frozen plasma as functional replacement therapy in early infantile ApoC-II deficiency: a molecularly confirmed case series.

Fresh frozen plasma as functional replacement therapy in early infantile ApoC-II deficiency: a molecularly confirmed case series.

Comparative efficacy and safety of olezarsen vs plozasiran for familial chylomicronemia syndrome: A matching-adjusted indirect comparison.

Comparative efficacy and safety of olezarsen vs plozasiran for familial chylomicronemia syndrome: A matching-adjusted indirect comparison.

Resolution of Refractory Multifocal Atrial Tachycardia in Costello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic.

Resolution of Refractory Multifocal Atrial Tachycardia in Costello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic.

Clinical and molecular characterization of 2 novel LPL variants in familial chylomicronemia syndrome.

Clinical and molecular characterization of 2 novel LPL variants in familial chylomicronemia syndrome.

Clinical and Molecular Portraits of Pediatric RASopathies: A Study of 118 Genotype-Confirmed Cases.

Clinical and Molecular Portraits of Pediatric RASopathies: A Study of 118 Genotype-Confirmed Cases.

2025: The year in cardiovascular disease - the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?

2025: The year in cardiovascular disease - the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?